查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924736

狂犬病免疫球蛋白市場按類型、給藥途徑、分銷管道和最終用戶分類 - 全球預測（2026-2032 年）

Rabies Immunoglobulins Market by Type, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年狂犬病免疫球蛋白市場價值為 8.0215 億美元，預計到 2026 年將成長至 8.562 億美元，年複合成長率為 8.11%，到 2032 年將達到 13.8547 億美元。

主要市場統計數據
基準年 2025 8.0215億美元
預計年份：2026年 8.562億美元
預測年份：2032年 13.8547億美元
複合年成長率 (%) 8.11%

在現代醫療保健服務中，確定狂犬病免疫球蛋白獲取的臨床和運營背景、供應鏈優先事項以及相關人員的需求

狂犬病是一項至關重要的公共衛生優先事項，及時注射免疫球蛋白可以挽救生命。圍繞這些治療的格局受到臨床緊迫性、不斷發展的生產模式和監管監督的共同影響。本導言闡述了狂犬病免疫球蛋白在暴露後預防中的臨床作用，並概述了相關人員必須關注的關鍵供應鏈、生產和臨床應用趨勢。此外，本導言也重點介紹了影響患者獲得治療的臨床實踐模式和分銷管道之間的相互作用。

生產製造創新、採購流程現代化和監管重點如何重塑狂犬病免疫球蛋白的供應、永續性和臨床實踐？

由於生物製造技術的進步、醫療系統採購方式的改變以及人們對公平獲取的期望日益提高，狂犬病免疫球蛋白市場正在經歷變革性變化。在生產方面，對更具可擴展性和可重複性的純化和分離技術的投資正在降低批間差異，提高安全性，並使製造商能夠更穩定地滿足嚴格的監管要求。同時，人們越來越關注能夠縮短生產週期並提高應對需求激增應對力的替代平台和製程強化策略。

檢驗美國新關稅和貿易合規變化如何促使供應鏈重組、採購轉移和採購調整。

2025年實施的政策變化和貿易措施給包括狂犬病免疫球蛋白在內的生物治療藥物的全球供應商和下游採購商帶來了新的成本和運營方面的考慮。不斷增加的關稅壓力和相關的合規要求提高了進口零件和成品的到岸成本，迫使供應鏈管理者重新評估其籌資策略和物流運作。為此，生產商和經銷商正在探索近岸外包、供應商多元化以及庫存管理方式的調整，以應對額外的財務和管理負擔。

確定產品類型、分銷管道、最終用戶環境和給藥途徑如何共同決定可訪問性、安全考慮因素和操作複雜性

了解產品細分的細微差別有助於理解治療屬性和分銷管道如何相互作用，從而決定臨床應用和營運的複雜性。根據類型，免疫球蛋白可分為馬源性和人源性，二者在臨床、安全性和生產方面各有其獨特的考量，這些考慮會影響採購選擇和臨床醫生的偏好。由於生產規模化，馬源性產品在某些情況下通常具有更廣泛的可用性，而人源性產品在許多司法管轄區更符合安全性認知和監管要求。

繪製出各區域獨特的優先事項和結構性限制因素圖，這些因素決定了狂犬病免疫球蛋白在全球的取得、採購和分發方式。

區域動態對美洲、歐洲、中東和非洲以及亞太地區的臨床用藥途徑、採購標準和監管預期有顯著影響，每個區域都有其獨特的優先事項和結構性限制。美洲通常集中擁有先進的低溫運輸物流和一體化的醫院採購系統，能夠保障都市區及時獲得醫療服務，而農村和偏遠社區則必須依賴有針對性的公共衛生干預措施。區域特徵也凸顯了影響處方箋決策的嚴格法律規範和支付方參與模式。

分析製造商、經銷商和醫療保健提供者之間不斷演變的競爭和合作模式，這些模式會影響供應鏈的連續性和分銷網路的覆蓋範圍。

隨著相關人員積極應對臨床需求模式、監管要求以及對供應韌性的迫切需求，製造商、經銷商和臨床供應商之間的競爭動態正在改變。成熟的馬源和人源免疫球蛋白生產商在生技藥品生產和監管申報方面擁有深厚的專業知識，並經常投資於製程改進，以提高安全性、均一性和產量。同時，新興參與企業和契約製造擁有製程強化和靈活的灌裝密封服務等能力，可以幫助縮短前置作業時間並實現本地化供應。

製造商、經銷商和醫療保健系統可採取的實際步驟，以增強免疫球蛋白療法的供應韌性、臨床可及性和監管準備。

產業領導者可以採取有針對性的措施，增強供應鏈韌性，改善臨床應用，並使商業策略與公共衛生優先事項保持一致。首先，投資多元化的製造地，並對關鍵原料和填充包裝服務進行二次認證，可以降低單點故障的風險，並能更靈活地應對需求波動。此外，提高庫存可視性，並在整個分銷網路中部署先進的溫度監控系統，可以減少廢棄物，並增強臨床用戶的信心。

一種多方面的調查方法，結合了專家訪談、監管審查和業務流程分析，以產生實際且檢驗的見解。

本研究採用系統性的多方法研究方法，整合了訪談、監管文件分析和業務流程審查，以確保為洞察和建議奠定堅實的基礎。透過與臨床醫生、供應鏈經理、採購負責人和生產專家進行深入訪談，收集一手數據，以了解他們對臨床實踐、分銷挑戰和生產能力的實際觀點。將這些定性數據與已發布的監管指南、臨床建議和貿易政策文件進行三角驗證，以檢驗發展趨勢並檢驗新出現的挑戰。

整合核心營運和臨床要務，並確保價值鏈各環節協調一致，以保障狂犬病免疫球蛋白的供應和病患療效。

總之，確保狂犬病免疫球蛋白的可靠供應需要採取協調一致的方法，涵蓋生產創新、分銷現代化和積極主動的籌資策略。及時給藥的臨床需求始終不變，而諸如來源多元化、提高低溫運輸可視性和臨床醫生培訓等營運措施對於維持供應至關重要。貿易政策的變化和關稅趨勢的演變帶來了額外的行政和成本方面的考量，各組織必須將這些因素納入其合約、供應計劃和風險管理框架中。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 狂犬病免疫球蛋白市場（按類型分類）

  • 馬
  • 人類

9. 狂犬病免疫球蛋白市場依給藥途徑分類

  • 浸潤
  • 肌肉內注射

第10章 狂犬病免疫球蛋白市場（依通路分類）

  • 離線
  • 線上

第11章 狂犬病免疫球蛋白市場（以最終用戶分類）

  • 診所
    • 政府診所
    • 私人診所
  • 醫院
    • 私立醫院
    • 公立醫院

12. 狂犬病免疫球蛋白市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 狂犬病免疫球蛋白市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國狂犬病免疫球蛋白市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國狂犬病免疫球蛋白市場

17. 中國的狂犬病免疫球蛋白市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bavarian Nordic A/S
  • Bayer AG
  • Bharat Serums and Vaccines Limited
  • Bio-Med Private Limited
  • BIoTest AG
  • Cadila Pharmaceuticals Limited
  • China Biologic Products Holdings, Inc.
  • CSL Behring LLC
  • GlaxoSmithKline plc
  • Grifols, SA
  • Hualan Biological Engineering, Inc.
  • Indian Immunologicals Limited
  • Kamada Ltd.
  • Kedrion Biopharma SpA
  • Octapharma AG
  • Sanofi Pasteur SA
  • Serum Institute of India Pvt. Ltd.
  • Shuanglin Bio-pharmaceutical Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Vins Bio Products Limited
Product Code: MRR-7A380DA7C465

The Rabies Immunoglobulins Market was valued at USD 802.15 million in 2025 and is projected to grow to USD 856.20 million in 2026, with a CAGR of 8.11%, reaching USD 1,385.47 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 802.15 million
Estimated Year [2026] USD 856.20 million
Forecast Year [2032] USD 1,385.47 million
CAGR (%) 8.11%

Establishing the clinical and operational context for rabies immunoglobulin access, supply chain priorities, and stakeholder imperatives in modern healthcare delivery

Rabies remains a critical public health priority where timely administration of immunoglobulins can be lifesaving, and the landscape for these therapeutics is shaped by clinical urgency, evolving production paradigms, and regulatory scrutiny. This introduction frames the clinical role of rabies immunoglobulins in post-exposure prophylaxis and outlines the principal supply chain, manufacturing, and clinical adoption dynamics that stakeholders must navigate. It also highlights intersections between clinical practice patterns and distribution channels that influence patient access.

Clinicians rely on immunoglobulins to provide immediate passive immunity while active vaccination elicits a protective response. Consequently, supply continuity, cold chain integrity, and appropriate clinical training represent practical imperatives. From a manufacturing perspective, production platforms for equine and human immunoglobulins differ in complexity and regulatory expectations, and these differences drive strategic choices for producers and health systems. Meanwhile, distribution frameworks spanning hospital and retail channels determine point-of-care availability and influence procurement strategies.

Transitioning from clinical fundamentals to operational considerations, the subsequent sections explore how market drivers, tariff implications, segmentation nuances, regional demand patterns, competitive dynamics, and recommended actions converge to shape near-term priorities for manufacturers, payers, and public health authorities.

How manufacturing innovation, procurement modernization, and regulatory emphasis are reshaping rabies immunoglobulin availability, resilience, and clinical practice

The rabies immunoglobulin landscape is experiencing transformative shifts driven by advances in biological manufacturing, changing procurement practices within health systems, and evolving expectations for equitable access. On the manufacturing front, investments in more scalable and reproducible purification and fractionation technologies are reducing lot-to-lot variability and improving safety profiles, enabling manufacturers to meet stringent regulatory requirements more consistently. Concurrently, there is growing interest in alternative platforms and process intensification strategies that can shorten production cycles and improve responsiveness to demand surges.

Procurement strategies are also shifting from transactional purchases toward integrated supply resilience planning, with hospitals and national programs favoring multi-sourcing arrangements and strategic stockpiling to mitigate disruptions. Digital tools for inventory management and temperature monitoring are increasingly integrated across distribution networks to reduce wastage and enhance traceability. In parallel, clinical practice is adapting as clinicians and public health practitioners emphasize timely administration and standardized protocols, supported by updated clinical guidance and training initiatives.

These shifts are further influenced by heightened regulatory attention to biologic safety and evolving reimbursement frameworks that aim to balance affordability with manufacturer sustainability. Taken together, these transformative forces are reshaping how products are developed, stocked, and administered, and they underscore the need for coordinated action across public and private stakeholders to preserve patient access and maintain high standards of care.

Examining how new tariff measures and trade compliance changes in the United States have prompted supply chain realignment, sourcing shifts, and procurement adaptation

Policy changes and trade instruments enacted in the United States during 2025 have introduced new cost and operational considerations for global suppliers and downstream purchasers of biologic therapeutics, including rabies immunoglobulins. Increased tariff pressures and associated compliance requirements have elevated landed costs for imported components and finished products, prompting supply chain managers to reassess sourcing strategies and logistics arrangements. In response, producers and distributors have explored nearshoring, supplier diversification, and changes in inventory policies to manage added financial and administrative burdens.

These tariff dynamics have also affected decisions around manufacturing footprint and procurement timing. Manufacturers that rely on cross-border flows for raw materials or fill-finish activities have faced added complexity in cost modeling and contractual negotiations. Health systems and public procurement entities have become more vigilant in scrutinizing total landed costs and delivery timeframes, which in some instances has lengthened lead times for contractual awards and prompted contingency arrangements to secure essential immunoglobulin stocks.

Importantly, regulatory compliance and customs documentation requirements introduced alongside tariff changes have increased administrative workload for suppliers and distributors, necessitating investment in customs expertise and trade compliance systems. While these shifts have not altered the clinical rationale for immunoglobulin administration, they have elevated the operational priority of supply chain visibility and contractual flexibility for organizations responsible for ensuring patient access.

Clarifying how type, distribution pathways, end user settings, and administration routes collectively define access, safety considerations, and operational complexity

A nuanced understanding of product segmentation clarifies how therapeutic characteristics and distribution pathways interact to determine clinical access and operational complexity. Based on type, the landscape differentiates between equine-derived immunoglobulins and human-derived immunoglobulins, each presenting distinct clinical, safety, and manufacturing considerations that inform procurement choices and clinician preferences. Equine products often offer broader availability in certain settings due to production scalability, while human products align closely with safety perceptions and regulatory expectations in many jurisdictions.

Based on distribution channel, availability is shaped across hospital pharmacy, online pharmacy, and retail pharmacy avenues. Hospital pharmacy pathways further delineate into private hospital pharmacy and public hospital pharmacy contexts, which diverge in procurement protocols, budget cycles, and stocking policies. Retail pharmacy distribution similarly splits into chain retail pharmacy and independent retail pharmacy operations, each with differing inventory management capabilities and ties to community healthcare providers. Online pharmacy models add another layer of complexity with remote ordering and logistics considerations that affect turn-around time and temperature-sensitive handling.

Based on end user, clinical delivery occurs through clinics and hospitals. Clinics are further categorized into government clinics and private clinics, reflecting divergent funding mechanisms, referral pathways, and formulary processes. Hospitals are similarly viewed through the lenses of private hospitals and public hospitals, where differences in purchasing power, tendering procedures, and emergency preparedness influence access. Finally, based on route of administration, practices typically follow infiltration or intramuscular approaches, with clinical guidance and training shaping route selection and administration protocols. Integrating these segmentation dimensions provides a practical framework for aligning manufacturing capacity, distribution strategies, and clinical education to improve patient access.

Mapping distinct regional priorities and structural constraints that determine how rabies immunoglobulins are accessed, procured, and distributed across global regions

Regional dynamics exert a powerful influence on clinical access, procurement norms, and regulatory expectations across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region displaying unique priorities and structural constraints. The Americas generally show a concentration of advanced cold chain logistics and integrated hospital procurement systems, which supports timely access in urban centers but leaves rural and remote communities reliant on targeted public health interventions. This regional profile also emphasizes stringent regulatory oversight and payer engagement models that shape formulary decisions.

Europe, Middle East & Africa encompasses a broad spectrum of healthcare system maturity, from highly centralized public procurement programs to fragmented private provider networks. In many countries, the priority is on equitable distribution and integration with primary care vaccination campaigns, while regulatory harmonization efforts aim to streamline approvals and pharmacovigilance. The Middle East component often features centralized procurement for public health programs, whereas parts of Africa contend with logistical hurdles and cold chain gaps that require donor and multilateral support.

Asia-Pacific presents diverse market structures with high-capacity manufacturing hubs in some countries and rapidly expanding healthcare access in others. National immunization priorities and local production capabilities influence procurement choices, and regional trade agreements can facilitate cross-border supply flows. Across all regions, public health priorities, infrastructure investments, and regulatory alignment determine how effectively rabies immunoglobulins reach patients in need.

Analyzing evolving competitive and partnership models among manufacturers, distributors, and healthcare providers that influence supply continuity and channel reach

Competitive dynamics among manufacturers, distributors, and clinical suppliers are evolving as stakeholders respond to clinical demand patterns, regulatory requirements, and supply resilience imperatives. Established producers of equine and human immunoglobulins maintain deep expertise in biologic production and regulatory submissions, and they often invest in process improvements to enhance safety, consistency, and yield. At the same time, emerging entrants and contract manufacturers bring capabilities in process intensification and flexible fill-finish services that can reduce lead times and support localized supply arrangements.

Distributors and hospital group purchasing organizations play an influential role in channel availability, leveraging scale to negotiate supply agreements and coordinate cold chain logistics. Pharmacy networks, both retail and online, are adapting inventory management and last-mile delivery processes to accommodate the temperature sensitivity of immunoglobulin therapies and to meet clinician expectations for timely access. Partnerships between manufacturers and national health programs or international agencies also influence distribution pathways, particularly where public health campaigns or outbreak responses necessitate coordinated logistics.

Across the value chain, strategic collaboration-whether through toll manufacturing agreements, joint procurement initiatives, or distribution partnerships-serves as a practical mechanism for spreading risk and improving responsiveness. These collaborative models are increasingly important as stakeholders seek to ensure continuity of supply while managing the administrative and cost implications introduced by recent trade and regulatory developments.

Actionable steps for manufacturers, distributors, and healthcare systems to enhance supply resilience, clinical access, and regulatory alignment for immunoglobulin therapies

Industry leaders can pursue targeted actions to strengthen supply resilience, improve clinical access, and align commercial strategies with public health priorities. First, investing in diversified manufacturing footprints and qualifying secondary sources for critical raw materials and fill-finish services helps to reduce single-point vulnerabilities and enables more agile responses to demand fluctuations. Complementary to this, enhancing inventory visibility across distribution networks and implementing advanced temperature-monitoring systems will reduce wastage and improve trust among clinical users.

Second, building stronger collaborations with hospital pharmacy networks, public procurement agencies, and clinic systems enables better alignment between production planning and clinical demand. These collaborations should include capacity-building initiatives that uplift clinical training on administration routes and handling protocols, which in turn helps to standardize practice and improve patient outcomes. Third, commercial teams should re-evaluate contracting terms to incorporate flexibility for tariff-related cost shifts and to embed contingency clauses that safeguard supply under changing trade regimes.

Finally, prioritizing data-driven regulatory engagement and pharmacovigilance cooperation can accelerate approvals for process improvements while maintaining safety standards. Together, these actions create a holistic approach that balances operational resilience, clinical reliability, and commercial viability while ensuring that patient access remains the central objective.

Description of the multi-method research approach combining expert interviews, regulatory review, and operational process analysis to produce actionable, validated insights

This research relies on a systematic, multi-method approach that integrates primary interviews, regulatory document analysis, and operational process reviews to ensure a robust foundation for insights and recommendations. Primary inputs were gathered through in-depth conversations with clinicians, supply chain leaders, procurement officers, and manufacturing specialists to capture actionable perspectives on clinical practice, distribution challenges, and production capabilities. These qualitative inputs were triangulated with publicly available regulatory guidance, clinical recommendations, and trade policy documents to validate trends and identify emergent issues.

Operational process reviews examined production pathways for equine and human immunoglobulins, distribution workflows across hospital and retail channels, and administration protocols in clinics and hospitals. Attention was paid to regulatory submission pathways, cold chain requirements, and the implications of tariff and trade compliance changes on cross-border logistics. Where applicable, case studies and anonymized procurement scenarios illustrated how organizations have adapted contracting and inventory strategies to maintain access during supply fluctuations.

Finally, findings were synthesized into actionable recommendations through iterative expert validation, ensuring that conclusions are grounded in practitioner experience and current policy frameworks. The methodology emphasizes transparency and traceability so stakeholders can understand the evidentiary basis for strategic guidance and apply it to operational planning and clinical program design.

Synthesis of core operational and clinical imperatives that must be coordinated across the value chain to preserve access and patient outcomes for rabies immunoglobulins

In conclusion, ensuring reliable access to rabies immunoglobulins requires a coordinated approach that spans manufacturing innovation, distribution modernization, and proactive procurement strategies. Clinical imperatives for timely administration remain unchanged, and operational measures such as diversified sourcing, enhanced cold chain visibility, and clinician training are essential to preserve access. Trade policy shifts and tariff developments have introduced additional administrative and cost considerations that organizations must integrate into contracting, supply planning, and risk management frameworks.

Regional differences in regulatory environments, healthcare infrastructure, and procurement practices necessitate tailored approaches that respect local priorities and logistical realities. Segmentation by product type, distribution channel, end user, and administration route provides a pragmatic lens for aligning production capacity with clinical need. Strategic collaboration across the value chain-whether through contracting arrangements, distribution partnerships, or capacity-building initiatives-can mitigate risk and improve responsiveness.

Moving forward, stakeholders who invest in supply resilience, regulatory engagement, and clinician education will be best positioned to safeguard patient outcomes and operational continuity. The recommendations presented here are intended to support evidence-informed decisions that balance safety, access, and commercial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rabies Immunoglobulins Market, by Type

  • 8.1. Equine
  • 8.2. Human

9. Rabies Immunoglobulins Market, by Route Of Administration

  • 9.1. Infiltration
  • 9.2. Intramuscular

10. Rabies Immunoglobulins Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Rabies Immunoglobulins Market, by End User

  • 11.1. Clinics
    • 11.1.1. Government Clinics
    • 11.1.2. Private Clinics
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals

12. Rabies Immunoglobulins Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Rabies Immunoglobulins Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rabies Immunoglobulins Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Rabies Immunoglobulins Market

16. China Rabies Immunoglobulins Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bavarian Nordic A/S
  • 17.6. Bayer AG
  • 17.7. Bharat Serums and Vaccines Limited
  • 17.8. Bio-Med Private Limited
  • 17.9. Biotest AG
  • 17.10. Cadila Pharmaceuticals Limited
  • 17.11. China Biologic Products Holdings, Inc.
  • 17.12. CSL Behring LLC
  • 17.13. GlaxoSmithKline plc
  • 17.14. Grifols, S.A.
  • 17.15. Hualan Biological Engineering, Inc.
  • 17.16. Indian Immunologicals Limited
  • 17.17. Kamada Ltd.
  • 17.18. Kedrion Biopharma S.p.A.
  • 17.19. Octapharma AG
  • 17.20. Sanofi Pasteur SA
  • 17.21. Serum Institute of India Pvt. Ltd.
  • 17.22. Shuanglin Bio-pharmaceutical Co., Ltd.
  • 17.23. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 17.24. Vins Bio Products Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RABIES IMMUNOGLOBULINS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RABIES IMMUNOGLOBULINS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GOVERNMENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GOVERNMENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GOVERNMENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 109. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. GCC RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. NATO RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)